Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy: initial experience in the Federal District

Abstract

Percutaneous transluminal septal alcoholization is effective and safe in the treatment of HOC.

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A Systematic Review of Published Studies

“…We included all the case series published in English and the English versions of foreign case series when available. A total of 42 studies/case series 10–21,24–27,33–58 were included in the final review. Inclusion criteria in these studies included symptomatic HOCM despite reported medical therapy, persistence of symptoms after dual chamber sequential pacing, or surgical myomectomy.…”

“…Alcohol septal ablation (ASA) is a new catheter‐based intervention that has been used as an alternative to surgical septal reduction 10–16 . ASA is performed through a percutaneous approach, in which 1–3 cc of absolute ethanol is introduced into a major septal artery to create a controlled septal infarction and necrosis at the base of the hypertrophied interventricular septum 17–23 .…”

Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy

“…AF confers increased risk of all‐cause mortality, including that due to heart failure and thromboembolic events and is associated with worsened exercise capacity and symptoms impacting quality of life . Despite multiple cohort studies of patients undergoing ASA for symptomatic HCM, , none has reported on the incidence of AF. We evaluated the incidence of AF following ASA for symptomatic HCM.…”